Jagsonpal Pharmaceuticals strengthens market position with acquisition of Yash Pharma

Mumbai (Maharashtra) (India), June 27: Jagsonpal Pharmaceuticals has announced the acquisition of Yash Pharma operations in India and Bhutan. Backed by boutique investment banking firm Growthally Advisors, the transaction is expected to not only expand Jagsonpal’s therapeutic footprint but will also have a strong impact on improving its position in the market.

This acquisition is all the more significant as it brings together two companies with complementary strengths. Jagsonpal has already built a 60-year legacy with a strong presence in gynaecology and orthopaedics. This is further strengthened with Yash Pharma’s established portfolio of 33 brands across dermatology and paediatrics becoming a part of their offering. This strategic move not only diversifies Jagsonpal’s product offering but also allows it to establish its presence in a new market segment worth Rs 20,000 crore (source: IQVIA) with significant growth opportunities available.

As Jagsonpal said in its investor presentation, “This acquisition is a perfect recipe for Jagsonpal. Yash Pharma’s strengths in dermatology and pediatrics can now be leveraged to align with our long-term growth goals. Now, with the expansion of our portfolio to include new customer segments, the company is poised to significantly strengthen its market position.”

Growth Advisors: Navigating this Strategic Growth Course

Growthally Advisors Pvt. Ltd., as a boutique investment banking firm with strong knowledge and expertise in the Indian pharmaceutical and healthcare markets, helped facilitate this seemingly complex transaction by leveraging its inherent expertise in executing mergers and acquisitions. Aligning their vision to deliver sustainable and profitable long-term growth was perfectly aligned with Jagsonpal’s needs.

Bhupinder Garg, Managing Director, Growthally Advisors, states, “We are proud to have contributed to this mutually rewarding partnership. We have always helped emerging Indian pharma and healthcare corporations achieve their long-term goals with innovative solutions that optimize their growth path. We believe this transaction is an excellent example of how strategic acquisitions can deliver benefits to all stakeholders.”

Ravi Jaisalmeria, Director, Growthally Advisors further added, “GrowthAlly has not limited its expertise to M&A advisory. They offer a comprehensive suite of services including private equity, debt syndication, startup fundraising, corporate leasing and CFO services. Through a holistic approach to empowering businesses throughout their development journey, clients receive both the strategic guidance and financial advice necessary to leverage emerging opportunities to achieve their long-term goals.

Shekhar Bhuwania, Director, GrowthAlly Advisors further stated, “The Indian pharma sector in particular will grow at a significant pace. Strategically planned collaborations and acquisitions will prove to be the main driving force in unlocking the enormous potential of this industry. This ensures that we always remain committed to working with companies that need help on this exciting journey in their ultimate pursuit of sustainable growth.

Mergers and Acquisitions: Their Role in Driving India’s Growth Story

As strategic partnerships and mergers are now becoming more common in the vast Indian pharmaceutical industry, it also requires utmost caution in the entire process. As pharmaceutical companies prepare to chart their course in an increasingly competitive market, a boutique banking firm like Growthally Advisors has an important role to play. This is thanks to their expertise in identifying and executing transactions that drive long-term value creation.

Mergers and Acquisitions: Driving Growth in the Indian Pharmaceutical Sector

Mergers and acquisitions have become commonplace in India’s rapidly growing pharmaceutical sector, which is expected to exceed $130 billion by 2030. In the first quarter of 2024 alone, 24 mergers and acquisitions transactions worth a total of USD 456.3 million have already been finalized (source: GlobalData transaction database). . This further highlights the collective desire of Indian pharmaceutical companies to diversify their portfolios, enter new markets and access innovative technologies.

The benefits are numerous: combining R&D capabilities can accelerate drug development while providing access to new technologies. Other benefits highlighted include increased market share, improved financial performance, as well as generating synergies through streamlined operations.

However, mergers and acquisitions in the pharmaceutical industry come with challenges. Integrating diverse company cultures and systems can be disruptive. Regulatory hurdles, including antitrust laws, can delay or derail the entire process. Additionally, pipeline risks and potential reputational damage can pose significant obstacles.

(ADVERTISING DISCLAIMER: The above press release was provided by PNN. ANI will not be responsible in any way for its content)

This story was auto-generated from a syndicated feed. ThePrint is not responsible for its content.